DRG Epidemiology’s coverage of Huntington’s disease (HD) comprises epidemiological estimates of key patient populations in seven emerging pharmaceutical markets (Brazil, Russia, India, China, Mexico, Turkey, and South Korea). We report the prevalence of the disease for each country, as well as annualized case counts projected to the national population.
DRG Epidemiology’s HD forecast will answer the following questions:
How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of HD over the forecast period?
All forecast data are available on the DRG Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is provided for full transparency into research and methods.
In addition to the total number of cases for each forecast year, DRG Epidemiology provides at least ten years of forecast data for the following HD subpopulations:
Diagnosed prevalence of premanifest HD.
Diagnosed prevalence of manifest HD.
Diagnosed incident cases of manifest HD.
Diagnosed population at risk.
Diagnosed prevalence of manifest HD by disease stage.
Diagnosed Prevalent Cases of Manifest Huntington's Disease per 100,000 People of All Ages in 2019 and 2029
Patient-Flow Diagram for Huntington's Disease in All Countries Under Study in 2019
Relative Sizes of the Contributing Factors to the Trend in Diagnosed Prevalent Cases of Manifest Huntington's Disease over the Next Ten Years
Diagnosed Population at Risk for Huntington's Disease
Diagnosed Incident Cases of Manifest Huntington's Disease
Diagnosed Prevalent Cases of Huntington's Disease
Diagnosed Prevalence of Huntington's Disease by Manifest Status
Diagnosed Prevalent Cases of Manifest Huntington's Disease by Disease Stage
Studies Included in the Analysis of Huntington's Disease
Studies Excluded from the Analysis of Huntington's Disease
Risk/Protective Factors for Huntington's Disease
Nishant Kumar, M.P.H.
Nishant Kumar, M.P.H., is a senior director on the Epidemiology team at Clarivate. His areas of expertise are oncology and CNS diseases, including Alzheimer’s disease and dementia. His key interests in oncology are modeling disease progression and drug-treatable incident and prevalent populations. Previously, Mr. Kumar sized patient populations for rare and niche diseases, such as graft-versus-host disease and Duchenne muscular dystrophy. He earned his M.P.H. with a concentration in epidemiology and statistics from King’s College in London and a B.Sc. (Honors) in medical studies from the University of Birmingham.
Mike Hughes, M.Sc., Ph.D.
Mike Hughes, M.Sc., Ph.D., is the director of the Epidemiology department at DRG, part of Clarivate. He joined DRG in 2006 and has many years’ experience in the mathematical modeling of healthcare service delivery, cardiovascular and cancer epidemiology, biostatistics, meta-analysis, and systematic reviewing. He has been principal author on many published articles in leading international journals in the areas of risk modeling in intensive care and cardiovascular medicine. He also helped develop national guidelines on behalf of NICE and the American College of Chest Physicians for the treatment of atrial fibrillation, stroke, and hypertension. He is particularly interested in modeling patient flows in cancer and methods for forecasting disease burden in noncommunicable epidemiology. Dr. Hughes received his Ph.D. in risk modeling in intensive care in 2003 from City University, London, and his Ph.D. in statistical causation and foundations of probability theory from the University of Nottingham.